TrialHuman vaccines & immunotherapeutics2022

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM

Subhash Thuluva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.